PHEN Webcast, August 13th at 6:00 pm ET
|
|
An Immunotherapy Vaccine to Prevent the Recurrence of Localized Prostate Cancer
|
The PHEN August webcast will present a potential breakthrough in preventing the recurrence of prostate cancer when treated at the localized level with the immunotherapy ProstAtak.
Presenter:
|
Webcast viewers will be able to submit questions via:
Email: Rapcancer@prostatehealthed.org
Facebook: ProstateHealthEducationNetwork
Please join the webcast on Wednesday, August 13, 2014, at 6:00 pm ET! Visit www.rapcancer.org.
|
|
About ProstAtak™
ProstAtak uses an innovative technique known as Gene Mediated Cytotoxic Immunotherapy (GMCI™) to kill tumor cells and stimulate a cancer vaccine effect. The idea is to "jump-start" the body's immune system so it can better detect and destroy residual cancer cells that pose a risk of the cancer returning. ProstAtak is designed to work together with standard radiation therapy and has resulted in lower than expected recurrence rates in earlier clinical trials. In a phase 2 study, the rate of recurrence was reduced from an expected 30% to 10%. At present, ProstAtak is the only vaccine product in development for preventing recurrence in localized prostate cancers.
ProstAtak is currently in a Phase 3 clinical trial under an FDA approved special protocol assessment (Fast-track), and is sponsored by Advantagene, Inc., a Boston, Massachusetts area biopharmaceutical company.
Join the webcast to learn more about ProstAtak and the phase 3 clinical trial.
|
